1. Docosahexaenoic acid-rich algae oil supplementation on breast milk fatty acid profile of mothers who delivered prematurely: a randomized clinical trial
- Author
-
Mireille Guillot, Isabelle Marc, David Simonyan, Iwona Rudkowska, Jean-François Bilodeau, Bruno Piedboeuf, Ibrahim Mohamed, Pierre Julien, Line Berthiaume, Pascal M. Lavoie, Hélène Fougère, and Etienne Pronovost
- Subjects
Adult ,medicine.medical_specialty ,Docosahexaenoic Acids ,030309 nutrition & dietetics ,Science ,Mothers ,030209 endocrinology & metabolism ,Breast milk ,Paediatric research ,Gastroenterology ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Chlorophyta ,Internal medicine ,medicine ,Humans ,Plant Oils ,chemistry.chemical_classification ,0303 health sciences ,Multidisciplinary ,Milk, Human ,business.industry ,Fatty Acids ,Infant, Newborn ,Fatty acid ,medicine.disease ,Lipids ,Eicosapentaenoic acid ,Clinical trial design ,3. Good health ,chemistry ,Bronchopulmonary dysplasia ,Docosahexaenoic acid ,Dietary Supplements ,Medicine ,Female ,Arachidonic acid ,Docosapentaenoic acid ,business ,Infant, Premature ,Polyunsaturated fatty acid - Abstract
Preterm infants are deficient in long-chain polyunsaturated fatty acids, especially docosahexaenoic acid (DHA), a fatty acid (FA) associated with an increase in bronchopulmonary dysplasia (BPD). In two previous randomized control trials, DHA supplementation did not reduce the risk of BPD. We examined the breast milk FA profile, collected 14 days after birth, of mothers who delivered before 29 weeks of gestation and who were supplemented with DHA-rich algae oil or a placebo within 72 h after birth as part of the MOBYDIck trial. Milk FA were analyzed by gas chromatography. The total amount of FA (mg/mL) was similar in both groups but the supplementation increased DHA (expressed as % of total FA, mean ± SD, treatment vs placebo, 0.95 ± 0.44% vs 0.34 ± 0.20%; P
- Published
- 2021